|
US5585481A
(en)
|
1987-09-21 |
1996-12-17 |
Gen-Probe Incorporated |
Linking reagents for nucleotide probes
|
|
US5378825A
(en)
|
1990-07-27 |
1995-01-03 |
Isis Pharmaceuticals, Inc. |
Backbone modified oligonucleotide analogs
|
|
ATE515510T1
(de)
|
1991-12-24 |
2011-07-15 |
Isis Pharmaceuticals Inc |
Durch dna-abschnitte unterbrochene modifizierte oligonukleotide
|
|
EP0760008A1
(en)
|
1994-05-19 |
1997-03-05 |
Dako A/S |
Pna probes for detection of neisseria gonorrhoeae and chlamydia trachomatis
|
|
PT2931898E
(pt)
|
2012-12-12 |
2016-06-16 |
Harvard College |
Manipulação e otimização de sistemas, métodos e composições para manipulação de sequências com domínios funcionais
|
|
WO2014093694A1
(en)
|
2012-12-12 |
2014-06-19 |
The Broad Institute, Inc. |
Crispr-cas nickase systems, methods and compositions for sequence manipulation in eukaryotes
|
|
IL308158A
(en)
|
2012-12-17 |
2023-12-01 |
Harvard College |
Rna-guided human genome engineering
|
|
US20150166984A1
(en)
|
2013-12-12 |
2015-06-18 |
President And Fellows Of Harvard College |
Methods for correcting alpha-antitrypsin point mutations
|
|
WO2015200555A2
(en)
|
2014-06-25 |
2015-12-30 |
Caribou Biosciences, Inc. |
Rna modification to engineer cas9 activity
|
|
CN106794141B
(zh)
|
2014-07-16 |
2021-05-28 |
诺华股份有限公司 |
将核酸包封在脂质纳米粒主体中的方法
|
|
AU2016226077B2
(en)
|
2015-03-03 |
2021-12-23 |
The General Hospital Corporation |
Engineered CRISPR-Cas9 nucleases with altered PAM specificity
|
|
EP3294342A4
(en)
*
|
2015-05-08 |
2018-11-07 |
President and Fellows of Harvard College |
Universal donor stem cells and related methods
|
|
AU2016262093B2
(en)
*
|
2015-05-13 |
2022-08-18 |
Seattle Children' S Hospital (Dba Seattle Children 's Research Institute) |
Enhancing endonuclease based gene editing in primary cells
|
|
WO2017093969A1
(en)
|
2015-12-04 |
2017-06-08 |
Novartis Ag |
Compositions and methods for immunooncology
|
|
WO2017136794A1
(en)
|
2016-02-03 |
2017-08-10 |
Massachusetts Institute Of Technology |
Structure-guided chemical modification of guide rna and its applications
|
|
ES3030658T3
(en)
|
2016-03-30 |
2025-07-01 |
Intellia Therapeutics Inc |
Lipid nanoparticle formulations for crispr/cas components
|
|
EP3551757A1
(en)
|
2016-12-08 |
2019-10-16 |
Intellia Therapeutics, Inc. |
Modified guide rnas
|
|
CN109790518A
(zh)
*
|
2017-05-08 |
2019-05-21 |
中国科学院动物研究所 |
经修饰的t细胞、其制备方法及用途
|
|
JP7170666B2
(ja)
|
2017-05-08 |
2022-11-14 |
プレシジョン バイオサイエンシズ,インク. |
操作された抗原受容体をコードする核酸分子及び阻害性核酸分子、並びにそれらの使用方法
|
|
US11738047B2
(en)
*
|
2017-12-12 |
2023-08-29 |
The Trustees Of The University Of Pennsylvania |
Genetically modified immune cells targeting NY-ESO-1 and methods of use thereof
|
|
WO2019147805A2
(en)
|
2018-01-26 |
2019-08-01 |
The Board Of Trustees Of The Leland Stanford Junior University |
Regulatory t cells targeted with chimeric antigen receptors
|
|
US11447769B2
(en)
|
2018-03-27 |
2022-09-20 |
The Trustees Of The University Of Pennsylvania |
Modified immune cells having enhanced function and methods for screening for same
|
|
JP7832761B2
(ja)
|
2018-06-08 |
2026-03-18 |
インテリア セラピューティクス,インコーポレイテッド |
遺伝子編集のための修飾されたガイドrna
|
|
EP3581200A1
(en)
|
2018-06-13 |
2019-12-18 |
GEMoaB Monoclonals GmbH |
Reversed universal chimeric antigen receptor expressing immune cells for targeting of diverse multiple antigens and method of manufacturing the same and use of the same for treatment of cancer, infections and autoimmune disorders
|
|
CA3116132A1
(en)
|
2018-10-16 |
2020-04-23 |
Intellia Therapeutics, Inc. |
Compositions and methods for immunotherapy
|
|
WO2020092057A1
(en)
|
2018-10-30 |
2020-05-07 |
Yale University |
Compositions and methods for rapid and modular generation of chimeric antigen receptor t cells
|
|
KR20230017783A
(ko)
|
2020-04-28 |
2023-02-06 |
인텔리아 테라퓨틱스, 인크. |
시험관내 세포 전달 방법
|